Development of rhabdomyosarcoma in HER-2/neu transgenic p53 mutant mice

Patrizia Nanni, Giordano Nicoletti, Carla De Giovanni, Stefania Croci, Annalisa Astolfi, Lorena Landuzzi, Emma Di Carlo, Manuela Iezzi, Piero Musiani, Pier Luigi Lollini

Research output: Contribution to journalArticle

Abstract

Rhabdomyosarcomas derive from the skeletal muscle lineage and harbor a variety of genetic and molecular lesions. However, it is not clear which molecular alterations have a pathogenetic role. We show that activation of the HER-2/neu oncogene coupled with inactivation of the oncosuppressor gene p53 causes rhabdomyosarcoma in mice. At the age of 11-21 weeks, all male mice carrying both genetic lesions developed embryonal rhabdomyosarcomas expressing desmin, myosin, and insulin-like growth factor-II, in the genitourinary tract. Our findings led to the hypothesis that the interaction between HER family genes and the p53 pathway might be involved in the origin of human rhabdomyosarcoma.

Original languageEnglish
Pages (from-to)2728-2732
Number of pages5
JournalCancer Research
Volume63
Issue number11
Publication statusPublished - Jun 1 2003

    Fingerprint

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Nanni, P., Nicoletti, G., De Giovanni, C., Croci, S., Astolfi, A., Landuzzi, L., Di Carlo, E., Iezzi, M., Musiani, P., & Lollini, P. L. (2003). Development of rhabdomyosarcoma in HER-2/neu transgenic p53 mutant mice. Cancer Research, 63(11), 2728-2732.